The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
The price of early stage cancer assets leaves Celgene shelling out $3.5bn in upfront payments, with no end in sight for rising valuations.